Tandem Diabetes Care (TNDM) Share-based Compensation (2013 - 2026)

Tandem Diabetes Care has reported Share-based Compensation for 14 years, with the latest figure at $15.7 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 38.56% year-over-year to $15.7 million; the trailing twelve-month figure through Mar 2026 stood at $82.6 million (down 21.25% YoY), and the FY2025 full-year result was $92.4 million, down 8.88% from the prior year.
• Share-based Compensation for Q1 2026 stood at $15.7 million, down from $20.1 million in the prior quarter.
• The five-year high for Share-based Compensation was $28.2 million in Q4 2024, with the low at $15.7 million in Q1 2026.
• Historically, Share-based Compensation has averaged $22.5 million across 5 years, with a median of $22.2 million in 2022.
• Annual changes were most pronounced in 2022 — Share-based Compensation surged 42.94% — and 2026, when it plunged 38.56%.
• Tandem Diabetes Care's Share-based Compensation stood at $24.4 million in 2022, then declined by 6.96% to $22.7 million in 2023, then advanced by 23.86% to $28.2 million in 2024, then decreased by 28.6% to $20.1 million in 2025, then declined by 22.13% to $15.7 million in 2026.
• The last three Share-based Compensation figures came in at $15.7 million (Q1 2026), $20.1 million (Q4 2025), and $21.1 million (Q3 2025), per Business Quant data.